Salarius Pharmaceuticals Files 8-K

TL;DR

Salarius Pharma filed an 8-K on Oct 6, 2025 for 'Other Events' - details TBD.

AI Summary

Salarius Pharmaceuticals, Inc. filed an 8-K on October 6, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself. The company is incorporated in Delaware and its principal executive offices are located in Houston, Texas.

Why It Matters

This 8-K filing indicates that Salarius Pharmaceuticals has reported an event requiring immediate disclosure to the SEC, though the specifics are not detailed in the provided text.

Risk Assessment

Risk Level: medium — The filing is an 8-K for 'Other Events' without specific details, which can imply significant but undisclosed developments.

Key Players & Entities

• Salarius Pharmaceuticals, Inc. (company) — Registrant
• October 6, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Houston, TX (location) — Principal Executive Offices
• 2450 Holcombe Blvd. Suite X (address) — Business Address

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
• $2.5 million — es the Company to maintain a minimum of $2.5 million in stockholders' equity for continued l
• $2.4 million — tock"), for aggregate gross proceeds of $2.4 million pursuant to that certain At the Market
• $3.8 million — n Stock for aggregate gross proceeds of $3.8 million pursuant to that certain Securities Pur

Filing Documents

• flks-20251006.htm (8-K) — 29KB
• 0001615219-25-000142.txt ( ) — 145KB
• flks-20251006.xsd (EX-101.SCH) — 2KB
• flks-20251006_lab.xml (EX-101.LAB) — 22KB
• flks-20251006_pre.xml (EX-101.PRE) — 13KB
• flks-20251006_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events As previously disclosed, Salarius Pharmaceuticals, Inc. (the "Company") has until October 20, 2025 to regain compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard"), which requires the Company to maintain a minimum of $2.5 million in stockholders' equity for continued listing on The Nasdaq Capital Market. Since June 30, 2025, the Company has issued and sold an aggregate of (i) 434,882 shares of its common stock, par value $0.0001 per share (the "Common Stock"), for aggregate gross proceeds of $2.4 million pursuant to that certain At the Market Offering Agreement, dated February 5, 2021, between the Company and Ladenburg Thalmann & Co. Inc.; and (ii) 367,887 shares of its Common Stock for aggregate gross proceeds of $3.8 million pursuant to that certain Securities Purchase Agreement, dated December 12, 2024, by and between the Company and C/M Capital Master Fund, LP. The Company believes that, as a result of the transactions described above, as of the date of this Current Report on Form 8-K, the Company's stockholders' equity exceeds $2.5 million. The Company anticipates that the information contained in its Quarterly Report on Form 10-Q for the period ended September 30, 2025 will reflect stockholders' equity in excess of $2.5 million as of September 30, 2025. The Company awaits Nasdaq's confirmation that the Company has successfully evidenced this compliance. The Company's determination of stockholders' equity is based on estimates and information available to it as of the date of this Current Report on Form 8-K, is not a comprehensive statement of its financial results or position as of or for the quarter ended September 30, 2025, and has not been audited, reviewed or compiled by the Company's independent registered public accounting firm. The Company's financial closing procedures for the quarter ended September 30, 2025, are not yet complete and, as a result, stockholders' equity upon completion of its closing proce

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements. Forward-looking statements may include, but are not limited to, statements related to whether the Company has regained compliance with the Equity Standard, which determination awaits Nasdaq's determination, and the Company's expectation that its stockholders' equity will continue to exceed $2.5 million at future dates, as well as statements, other than historical facts, that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this Current Report on Form 8-K are made as of the date of this Current Report on Form 8-K, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the Company's control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include factors such as the Company's history of noncompliance with Nasdaq listing standards and the absence of any guarantee that there will not

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: October 6, 2025 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Acting Chief Executive Officer Executive Vice President & Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR